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ABSTRACT 
 
Numerous reported data support the idea that Brain Derived Neurotrophic Factor (BDNF) is 
critically involved in both depression and comorbid pain. The possible direct effect of BDNF 
on pain mechanisms was assessed here and compared with behavioral/neurobiological 
features of neuropathic pain caused by chronic constriction injury to the sciatic nerve (CCI-
SN). Sprague-Dawley male rats were either injected intrathecally with BDNF (3.0 ng i.t.) or 
subjected to unilateral CCI-SN. Their respective responses to anti-hyperalgesic drugs were 
assessed using the Randall-Selitto test and both immunohistochemical and RT-qPCR 
approaches were used to investigate molecular/cellular mechanisms underlying hyperalgesia 
in both models. Long lasting hyperalgesia and allodynia were induced by i.t. BDNF in intact 
healthy rats like those found after CCI-SN. Acute treatment with the BDNF-TrkB receptor 
antagonist cyclotraxin B completely prevented i.t. BDNF-induced hyperalgesia and partially 
reversed this symptom in both BDNF-pretreated and CCI-SN lesioned rats. Acute 
administration of the anticonvulsant pregabalin, the NMDA receptor antagonist ketamine, 
the opioid analgesics morphine and tapentadol or the antidepressant agomelatine also 
transiently reversed hyperalgesia in both i.t. BDNF injected- and CCI-SN lesioned-rats. 
Marked induction of microglia activation markers (OX42, Iba1, P-p38), proinflammatory 
cytokine IL-6, NMDA receptor subunit NR2B and BDNF was found in spinal cord and/or 
dorsal root ganglia of CCI-SN rats. A long lasting spinal BDNF overexpression was also 
observed in BDNF i.t. rats, indicating an autocrine self-induction, with downstream long 
lasting TrkB-mediated neuropathic-like pain. Accordingly, TrkB blockade appeared as a 
relevant approach to alleviate not only i.t. BDNF- but also nerve lesion-evoked neuropathic 
pain.   
 
Key words: BDNF, neuropathic pain, chronic constriction injury, microglia activation, TrkB 
receptor, cyclotraxin B 
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1 - Introduction  
Comorbidity between depression and chronic neuropathic pain has been repeatedly 
reported in the relevant literature, suggesting the existence of at least some common 
underlying mechanisms (Chopra and Arora, 2014). In support with this inference, first line 
treatment of chronic neuropathic pain is based on effective antidepressant drugs, especially 
tricyclics and mixed inhibitors of noradrenaline and serotonin reuptake  (Finnerup et al., 
2015). However, whether antidepressant drugs really act through a facilitation of 
monoaminergic neurotransmission to reduce neuropathic pain is still a matter of debate. 
Indeed, these drugs can also affect neuroinflammatory processes, interact directly with 
voltage-dependent cation channels involved in the transmission of nociceptive signals and 
block some pain-related receptors, and these actions might also contribute to their anti-
neuropathic pain properties (Vranken, 2012). 
Among endogenous molecules involved in both depression and antidepressants’ action on 
the one hand, and chronic pain on the other hand, the neurotrophin Brain Derived 
Neurotrophic Factor (BDNF) seems to play cardinal roles (Pezet and McMahon, 2006; Autry 
and Monteggia, 2012). A large consensus has led to the conclusion that depression is 
associated with BDNF downregulation in brain areas such as the hippocampus and the 
frontal cortex (Cai et al., 2015), and it has been recently proposed that depression-like 
behavior caused by some pro-inflammatory cytokines might be underlain by their capacity to 
downregulate hippocampal BDNF (Calabrese et al., 2014). Conversely, antidepressants, 
including the atypical antidepressant ketamine, have been shown to enhance BDNF 
production, or even transactivate the BDNF-TrkB (tropomyosin receptor kinase B) receptor, 
thereby counteracting depression-associated BDNF-TrkB downregulation (Lindholm and 
Castrén, 2014). That antidepressants could act through supraspinal BDNF-TrkB activation is 
supported by data showing that direct intracerebral administration of BDNF itself exerts 
antidepressant-like effects in validated rodent models of depression (Shirayama et al., 2002).   
However, it would be irrelevant to infer that an upregulation of BDNF always contributes to 
an antidepressant action because direct injection of BDNF into the ventral tegmental area 
was found to cause depression-like behavior, whereas BDNF signaling blockade in the 
nucleus accumbens produced antidepressant-like effects (Berton et al., 2006).  
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Regarding pain, the role of BDNF is also a matter of debate because both antinociceptive 
(Cejas et al., 2000; Lever et al., 2003) and pronociceptive (Groth and Aanonsen, 2002; 
Constandil et al., 2011, 2012) effects have been reported after direct administration of this 
neurotrophin intracerebroventricularly or intrathecally (i.t.) in rodents. Furthermore, 
inflammatory but not neuropathic pain seems to implicate BDNF (Zhao et al., 2006), which 
may suggest that the anti-neuropathic pain effect of antidepressants would not involve this 
neurotrophin, in line with a recent report showing that the antihyperalgesic effect of 
amitriptyline was not associated with any change of spinal BDNF levels in CCI-SN rats 
(Vanelderen et al., 2013).   
All these rather heterogeneous data led us to reinvestigate the effects of direct 
administration of BDNF at spinal level for a thorough comparison with authentic neuropathic 
pain symptoms caused by unilateral chronic constriction injury to the sciatic nerve (CCI-SN) 
in rats. In particular, drugs known to be effective to alleviate neuropathic pain, especially 
antidepressants, anticonvulsants and opioids (Finnerup et al., 2015) were tested in both 
BDNF-treated and CCI-SN-lesioned rats. In addition, quantitative RT-PCR and 
immunohistochemistry were used to investigate whether microglial and neuroplasticity 
markers were affected in BDNF i.t. rats like that previously described in CCI-SN rats 
(Latrémolière et al., 2008). Finally, whether BDNF-TrkB blockade by cyclotraxin B (Cazorla et 
al., 2010) could antagonize not only BDNF i.t.- but also CCI-SN-induced 
allodynia/hyperalgesia was also assessed.   
 
2. Experimental procedures 
2.1. Animals  
Adult male Sprague-Dawley rats (175-200 g on arrival from Charles River Breeding Center, 
69210 L’Arbresle, France) were housed in a controlled environment (22°± 1 °C, 60% relative 
humidity, 12:12 h light-dark cycle, lights on at 7:00 a.m.) with food and water available ad 
libitum, under resting conditions (no handling) for at least 1 week before experiments. All 
experiments were performed in conformity with the Guidelines of the Committee for 
Research and Ethical Issues of the International Association for the Study of Pain 
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(Zimmermann, 1983) and strictly followed the Institutional Guidelines that are in compliance 
with national and international laws and policies for use of animals in neuroscience research 
(Council Directive 86/609/EEC of the the European Communities, November 24, 1986; 
Council Directive 87-848 of the French Ministère de l’Agriculture et de la Forêt, Service 
vétérinaire de la santé et de la protection animale, October 19, 1987; permissions nb 
A752128 to S.M., nb 75 116 to M.H., nb 006228 to S.B.).  
2.2. Surgery 
2.2.1. Chronic constriction injury to the sciatic nerve 
Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and unilateral CCI-SN was 
made according to the procedure of Bennett and Xie (1988). Briefly, the right common 
sciatic nerve was exposed at mid-thigh level and freed from adhering tissue allowing the 
disposition of four ligatures (5.0 silk suture) tied loosely with 1 mm spacing. Sham rats 
underwent the same surgery without ligatures. Muscle and skin were then closed in layers 
with silk suture (4.0) and rats were allowed to recover for one week in their home cage.  
2.2.2.  Intrathecal injection 
Rats were slightly anesthetized using isoflurane (3% in air) and injected into the 
subarachnoid space between L5 and L6 vertebrae using a 26 G needle connected to a 
Hamilton syringe (Mestre et al., 1994). Each rat received 12 µL of vehicle (0.9% NaCl) or 
BDNF solution (“BDNF i.t.”, Peprotech, 92200 Neuilly, France). The dose of BDNF (3.0 ng/12 
µL of saline) was selected from previous studies (Groth and Aanonsen, 2002; Constandil et 
al., 2011, 2012).  
2.3. Behavioral tests 
All tests were performed by an experienced person blind to treatment groups. 
2.3.1.  Paw pressure test 
Mechanical nociceptive thresholds, expressed as grams (g), were measured using an Ugo 
Basile algesimeter (Bioseb, 92370 Chaville, France) according to Randall and Selitto (1957). 
Pressure thresholds to trigger paw withdrawal then vocalization (Kayser et al., 2010) were 
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determined on the day before nerve injury or intrathecal injection (basal values) and then on 
day 15 after surgery for CCI-SN rats or on day 10 after i.t. injection for BDNF i.t. rats, when 
hypersensitivity to mechanical stimulation had fully developed (see Results). 
Pharmacological treatments started immediately thereafter, and thresholds were 
determined at regular time intervals (30 or 60 min) after drug administration. Only animals 
showing clear-cut mechanical hypersensitivity (approximately 60% of CCI-SN rats and 80% of 
BDNF i.t. rats), with a reduction of nociceptive thresholds of at least 30% compared to sham-
operated/vehicle i.t. rats, were used for pharmacological studies.  
2.3.2.  von Frey filaments test 
Each rat was first habituated for two hours in a quiet room, and mechanical sensitivity was 
then determined with a graded series of eight von Frey filaments (4, 6, 8, 10, 12, 15, 26 and 
60 g; Latrémolière et al., 2008) applied to the lateral plantar surface of hindpaw (ipsilateral 
to CCI-SN, bilaterally in BDNF i.t. rats). The up-down procedure of Chaplan et al. (1994) was 
used to determine the pressure threshold to trigger hindpaw withdrawal. When no response 
was observed, the force of the thickest filament (60 g) was arbitrarily assigned as the “cut-
off” value (see Latrémolière et al., 2008).  
2.4.  Pharmacological treatments 
Cyclotraxin B (Bio S&T, Montreal, Canada), pregabalin (Sequoia, Pangbourne, UK), morphine 
(Pharmacie Centrale des Hôpitaux de Paris, France), tapentadol (Grünenthal, Aachen, 
Germany), agomelatine (Servier, Suresnes, France), ketamine, duloxetine and amitriptyline 
(Sigma-Aldrich, Saint-Quentin Fallavier, France), clonazepam (Roche, Basel, Switzerland) 
were administered using routes and doses previously reported to be active at their 
respective molecular targets  (Cazorla et al., 2010; de Bodinat et al., 2010; Lau et al., 2013; 
Michot et al., 2013; M’Dahoma et al., 2014). Drugs were injected i.p. in a volume of 1 mL/kg, 
except morphine which was injected subcutaneously (1 mL/kg, s.c.). Cyclotraxin B, 
morphine, tapentadol, pregabalin, ketamine and amitriptyline were dissolved in 0.9 % NaCl. 
Agomelatine and duloxetine were dissolved in 1% hydroxyethylcellulose (HEC) in water, and 
clonazepam in ethanol:water (50:50). Control animals received respective vehicles using the 
same routes of administration. 
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2.5. Immunohistochemistry 
 
2.5.1. Stroking stimulation  
Previous studies showed that gentle (non noxious) mechanical stimulation of hindpaw 
allowed immunocytochemical visualization of neuronal sensitization underlying 
hyperalgesia/allodynia-like responses in rats (Kayser et al., 2010). This protocol was used 
here to look for possible neuronal sensitization at spinal level in rats that had been i.t. 
injected with BDNF 10 days before. Briefly, gentle touch stimulus with a paint brush was 
applied once every 10 sec for 10 min to the right hindpaw. This touch stimulus feels like a 
stroke in human volunteers and does not elicit a flexion reflex in naïve healthy rats. Such 
stroking stimulation was performed 24 h before deep anesthesia and perfusion for 
immunohistochemical procedure (2.5.2.). 
 
2.5.2. Immunohistochemical procedure 
Fifteen days after CCI-SN and 11 days after i.t. BDNF, rats were deeply anesthetized with 
pentobarbital (50 mg/kg i.p.) and perfused intracardially with a heparin (25 IU/ml)-saline 
solution, followed by 0.12 M phosphate buffered saline (PBS, pH 7.4) containing 4% 
paraformaldehyde, 0.1% glutaraldehyde and 0.05% picric acid, and finally by 20% sucrose 
solution. The spinal cord was removed and cryoprotected in 20% sucrose solution overnight. 
Coronal floating sections (30 µm thick) of the lumbar enlargement were collected and then 
processed in parallel, with the same reagents, under the very same conditions (see Kayser et 
al., 2010). To label phospho-p38 (P-p38), the activated form of p38 MAP kinase (Jin et al., 
2003), sections were incubated with the primary antibody (rabbit anti-P-p38, 1/3,000, Cell 
Signaling Inc, Danvers, MA, USA) in PBS-T-azide (0.02 M PBS containing 0.3% Triton X-100 
and 0.02% sodium azide) overnight at room temperature. After rinsing with PBS, the sections 
were incubated for 1 h with the secondary antibody (biotinylated goat anti-rabbit, 1/1,000, 
Vector, Burlingame, CA, USA) in PBS containing 0.3% Triton X-100, then  rinsed again with 
PBS and finally incubated for 1 h in the avidin-biotin horseradish-peroxidase solution (ABC 
Vectastain kit Elite, Vector). Immunolabeling was revealed with peroxidase substrate kit (SK-
4100, Vector), and sections were sequentially treated with 50%, 70%, 90%, 95% absolute 
ethanol and xylene, before cover-slipping with Eukitt (Sigma-Aldrich, St Louis, MO, USA). P-
p38 immunoreactive cells within the superficial (I-II) and deep (III-V)  laminae of the dorsal 
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horn were counted in each 30 µm thick coronal section every 180 µm at L4-L6 levels using 
the software Mercator (see Kayser et al., 2010).  
 
2.6. Real time quantitative RT-PCR 
BDNF i.t. rats (24 h and 10 days after i.t. injection), CCI-SN rats (15 days after surgery) and 
their respective controls were killed by decapitation. Dorsal root ganglia (DRG, on the right 
side in CCI-SN rats) and the dorsal half of the lumbar cord (ipsilateral dorsal quadrant for CCI-
SN rats) at L4-L6 were rapidly dissected at 0-4 °C, and immediately frozen in liquid nitrogen 
to be stored at -80 °C. Total RNA was extracted using the NucleoSpin RNA II extraction kit 
(Macherey-Nagel, 67722 Hoerdt, France) and quantified using a NanoDrop. First-stranded 
cDNA synthesis was carried out using High capacity cDNA reverse transcription kit (Applied 
Biosystems, Courtaboeuf, France). PCR amplification, in triplicate for each sample, was 
performed using ABI Prism 7300 (Applied Biosystems), TaqMan® Universal PCR Master Mix 
No AmpErase® UNG (Applied Biosystems) and Assays-on-Demand Gene Expression probes 
(Applied Biosystems) for target genes: ATF3 (assay ID Rn00563784_m1), OX-42 
(Rn00709342_m1), GFAP (Rn01460868_m1), IL-6 (Rn00561420_m1), Iba1 (Rn00574125_g1), 
BDNF exon IX (Rn02531967_s1) and NR2B (Rn00680474_m1) subunit of NMDA receptors. 
Semi-quantitative determinations were made with reference to the reporter gene encoding 
glyceraldehyde 3-phosphate dehydrogenase (GaPDH; Rn99999916_s1). The polymerase 
activation step at 95°C for 15 min was followed by 40 cycles of 15 sec at 95°C and 60 sec at 
60°C. Data are presented as relative mRNA units compared with control values (see 
Latrémolière et al., 2008). 
 
2.7. Statistical analyses  
All values are expressed as mean ± S.E.M.  Areas under the time-course curves (AUC) were 
calculated using the trapezoidal rule. Statistical significance of the pressure threshold data 
was analyzed by 1-way ANOVA with repeated measures (effect of BDNF over time) followed 
by a Fisher’s Protected Least Significant Difference (PLSD) test or a 2-way ANOVA (with 
factor treatment and repeated measures over time) followed by Bonferroni test. For RT-
qPCR data, the 2-ΔΔCt method (Schmittgen and Livak, 2008) was used to analyze the relative 
changes in specific mRNA levels. The Student’s t test was used to compare 
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immunohistochemical and RT-qPCR data in treated versus control group when only 2 groups 
were analysed. A 1-way ANOVA followed by a Newman Keuls test was used when 
comparison was made between 3 or more groups.  In all cases, significance level was set at P 
< 0.05. 
 
 
3. Results  
 
3.1. Time course development of mechanical hyperalgesia and allodynia in CCI-SN 
and BDNF i.t. rats.  
CCI-SN induced a progressively developing mechanical hyperalgesia at the ipsilateral 
hindpaw that reached its maximal intensity two weeks after surgery (Fig. 1 A). BDNF i.t. also 
induced mechanical hyperalgesia, but more rapidly than CCI-SN, since the maximal decrease 
in pressure threshold values determined with the Randall-Selitto test was reached as soon as 
one week post injection (Fig. 1B). As shown in figure 2, the intensity of mechanical 
hyperalgesia as assessed from maximal decreases in pressure threshold values to trigger 
hindpaw withdrawal (-33.9 %, P<0.001) and vocalization (-36.9%, P<0.01) in BDNF i.t. versus 
saline i.t. rats was similar to that found in CCI-SN versus sham-operated rats (-33.4%, P<0.05, 
and -35.8%, P<0.001, respectively). Furthermore, like that occurring after CCI-SN, mechanical 
hyperalgesia evoked by i.t. BDNF was a long lasting response which persisted for at least one 
month post-injection (Fig. 1B). 
Von Frey filaments test showed that mechanical allodynia also developed after CCI-SN (Fig. 
1C) and BDNF i.t. (Fig. 1D). Indeed, allodynia was as pronounced and lasted for at least four 
weeks under either condition (Fig. 1C,1D).  However, maximal allodynia-like response was 
reached much earlier in BDNF i.t.- than in CCI-SN-rats (Fig. 1D compared to Fig. 1C). 
 
3.2. Effects of various drugs on mechanical hyperalgesia in BDNF i.t. versus CCI-SN- 
rats 
 
3.2.1. Effects of antihyperalgesic drugs, pregabalin and ketamine 
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Two weeks after CCI-SN or 10 days after i.t. BDNF, acute treatment with pregabalin (30 
mg/kg i.p.) significantly reduced hyperalgesia as shown by the return of pressure threshold 
values up to the range observed in naïve healthy rats subjected to the Randall-Selitto test 
(Fig. 3A,3B). Similar time courses of the drug effect were observed in both models, with 
complete reversal of hyperalgesia at 2-3 hours post-treatment, followed by its progressive 
reappearance down to pre-treatment threshold values 24 h after pregabalin administration 
(Fig. 3A,3B). Ketamine (50 mg/kg i.p.) also reduced hyperalgesia in both models (Fig. 3C,3D), 
but its effects were less pronounced and of shorter duration than pregabalin (Fig. 3C,3D). 
3.2.2. Effects of opioid receptor agonists, morphine and tapentadol 
In both CCI-SN- and BDNF i.t.- rats, acute treatment with morphine (3 mg/kg s.c., Fig. 4A,4B)  
and tapentadol (10 mg/kg i.p., Fig. 4C,4D) also reduced mechanical hyperalgesia as shown by 
significant increases in pressure threshold values to trigger vocalization in the Randall-Selitto 
test. Complete reversal of hyperalgesia was observed up to one hour after morphine 
administration, but this effect vanished rapidly and was no longer significant one hour later 
(Fig. 4A,4B). As shown in figure 4C,4D, the effect of tapentadol was even more transient 
since it had completely disappeared 90 min after the drug administration. 
3.2.3. Effects of agomelatine, amitriptyline, duloxetine and clonazepam 
As shown in figure 5A,5B, acute administration of the antidepressant agomelatine (45 
mg/kg, i.p.) significantly reduced mechanical hyperalgesia in both CCI-SN- and BDNF i.t.- rats. 
These effects were transient since partial recovery of pretreatment threshold values was 
already observed 30 (Fig. 5B) or 30-60 min (Fig. 5A) after the drug administration.  
In contrast with agomelatine, the tricyclic antidepressant amitriptyline (10 mg/kg i.p.) did 
not significantly affect pressure threshold values at any time up to four hours post-
treatment in both CCI-SN- and BDNF i.t.- rats (Fig. 5C,5D). Similarly, neither duloxetine (10 
mg/kg i.p.), nor clonazepam (0.25 mg/kg i.p.) significantly affected pressure threshold values 
to trigger vocalization in both CCI-SN- and BDNF i.t.- rats (not shown).  
  
3.3. Effects of TrkB receptor blockade by cyclotraxin B  
3.3.1. Prevention by cyclotraxin B of BDNF i.t.- induced hyperalgesia  
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When administered twice, 15 min before and 15 min after i.t. injection of BDNF,  cyclotraxin 
B, at an effective dose (20 mg/kg i.p.) to block BDNF-TrkB receptor in the central nervous 
system (Cazorla et al., 2010), prevented the hyperalgesic-like effect normally induced by the 
trophic factor. As shown in figure 6, the BDNF-induced decrease in pressure threshold values 
to trigger hindpaw withdrawal (Fig. 6A) and vocalization (Fig. 6B) in the Randall-Selitto test 
did not occur for at least one week after cyclotraxin-B administration. On its own, cyclotraxin 
B did not significantly affect pressure threshold values in naïve rats (not shown). 
3.3.2. Reversal by cyclotraxin B of CCI-SN- and BDNF i.t.-induced hyperalgesia  
 
When injected two weeks after surgery in CCI-SN rats, cyclotraxin B (two injections at 20 
mg/kg i.p., 30 min apart) reversed partially the nerve lesion-induced decrease in pressure 
threshold value to trigger vocalization in the Randall-Selitto test. As shown in figure 7A,7C, 
this anti-hyperalgesic effect developed progressively in CCI-SN rats, up to a maximum 1-5 
days after cyclotraxin B, which corresponded to half-recovery of healthy control mechanical 
sensitivity (C on abscissa). Thereafter, the effect of cyclotraxin B decreased progressively and 
was no longer significant on day 10 post-injection (Fig. 7A).  
Similarly, cyclotraxin B increased the pressure threshold value to trigger vocalization in rats 
which had developed hyperalgesia 10 days after BDNF i.t. (Fig. 7B,7D). At its maximum, on 
days 1-5 post-treatment, cyclotraxin B effect corresponded to half-reversal of BDNF i.t.-
induced hyperalgesia. Thereafter, this effect progressively vanished and hyperalgesia 
returned to pretreatment level on day 8 post-injection (Fig. 7B).  
 
3.4. Neuroinflammation/glial activation markers in the spinal cord and dorsal root 
ganglia of CCI-SN- versus BDNF i.t.- rats 
 
In CCI-SN rats, significant upregulation of transcripts encoding the neuronal injury marker 
ATF3 and the microglia activation markers OX-42 and Iba1 was observed in both the 
ipsilateral dorsal quadrant of the lumbar enlargement of the spinal cord (x 8.57, P < 0.01; x 
2.56, P < 0.001; x 1.47, P<0.01, respectively) and ipsilateral L4-L6 DRG (x 16.33, P < 0.001; x 
1.76, P < 0.05; x 1.62, P < 0.05, respectively) two weeks after surgery (Fig. 8). In contrast, one 
day (not shown) as well as 10 days (Fig. 8) post-injection, when hyperalgesia and allodynia 
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had reached their maximal intensities (see Fig. 1B,1D), no changes in spinal cord and DRG 
levels of mRNAs encoding ATF3, OX-42 and Iba1 were detected in BDNF i.t. rats.  
Data in figure 8 also show that CCI-SN induced significant upregulation of mRNAs encoding 
IL-6, BDNF and the NR2B subunit of NMDA receptors in both the ipsilateral dorsal quadrant 
of the lumbar enlargement of the spinal cord (x 3.68, P < 0.001; x 1.62, P < 0.05; x 1.44, P < 
0.05, respectively) and L4-L6 DRG (x 15.43, P < 0.001; x 1.66, P < 0.05; x 1.67, P < 0.05, 
respectively) (Fig. 8). BDNF mRNA upregulation was also observed in the dorsal half of the 
lumbar enlargement (x 1.42, P < 0.01), but not in L4-L6 DRG, of rats with 
hyperalgesia/allodynia on day 10 post BDNF i.t. (Fig. 8). In contrast, neither IL-6 mRNA nor 
NR2B mRNA at spinal and DRG levels were significantly changed in BDNF i.t. rats (Fig. 8), and 
GFAP mRNA remained unaffected by CCI-SN or BDNF i.t. under our experimental conditions  
(Fig.8, and data not shown). 
 
3.5. Immunohistochemical labeling of P-p38 at spinal level in CCI-SN- versus BDNF 
i.t.- rats 
At L4-L6 level of the lumbar enlargement of the spinal cord, a significant increase in the 
density of P-p38 immunoreactive cells was observed within both superficial (I-II) and deep 
(III-V) laminae of the dorsal horn ipsilateral to the surgery in CCI-SN- compared to sham-
operated-rats (Fig. 9A). A significant increase in P-p38 immunolabeling was also observed 
within the contralateral dorsal horn, but of lower amplitude (CCI-SN vs sham, laminae I-II: + 
26.7 ± 8.7 %, P < 0.01; laminae III-V: + 64.7 ± 10.8 %, P < 0.01, not shown) than that observed 
in the ipsilateral dorsal horn (CCI-SN vs sham, laminae I-II: + 64.0 ± 8.8 %, P < 0.001; laminae 
III-V: +145.2 ± 11.6 %, P < 0.001) (Fig. 9A). In contrast, no significant change in P-p38 
immunostaining was detected within the dorsal horn of the lumbar enlargement in BDNF i.t. 
rats (Fig. 9B). However, stroking stimulation of the right hindpaw under conditions that did 
not affect P-p38 immunolabeling in control (saline i.t.) rats did produce significant increases 
in the density of P-p38 immunoreactive cells within both the superficial laminae I-II and deep 
laminae III-V of the ipsilateral dorsal horn in BDNF i.t. rats (Fig. 9B).  
 
4. Discussion 
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Our data showed that spinal administration of BDNF triggered sustained hyperalgesia- and 
allodynia-like behaviors in naïve healthy rats to the same extent as CCI-SN, further 
supporting the idea that this neurotrophin plays a cardinal role in physiopathological 
mechanisms underlying neuropathic pain (Pezet and McMahon, 2006). In both BDNF i.t.- and 
CCI-SN-rats, activation of BDNF TrkB receptor appeared to play a key role in the maintenance 
of neuropathic-like pain because systemic administration of cyclotraxin B, at a dose (2 x 20 
mg/kg i.p.) blocking TrkB in the central nervous system (Cazorla et al., 2010), significantly 
reduced hyperalgesia. Interestingly, the antihyperalgesic effect of cyclotraxin B lasted for at 
least 5 days after its administration, showing the powerful efficacy of blocking BDNF/TrkB 
signaling pathway to relieve neuropathic-like pain. Such a long lasting effect of cyclotraxin B, 
which confirmed previous data obtained in rats with infraorbital nerve ligation or injected 
intracisternally with BDNF (Constandil et al., 2012), might be explained by the capacity of 
TrkB blockade to prevent synaptic sensitization underlying hyperalgesic processes. Indeed, 
long term potentiation (LTP), that can be induced by BDNF at spinal level (Zhou et al., 2010), 
plays a key role in synaptic sensitization and the blockade by cyclotraxin B of BDNF action 
might suppress the occurrence of LTP at spinal level.  To date, however, the capacity of 
cyclotraxin B to prevent BDNF-induced LTP has been demonstrated in the hippocampus only 
(Cazorla et al., 2010).  
Interestingly, TrkB receptor blockade by cyclotraxin B, at a dose (2 x 20 mg/kg i.p.) 
preventing completely the development of BDNF i.t.-induced hyperalgesia (Fig. 6), only 
partially reversed hyperalgesia once this neuropathic pain-related symptom had fully 
developed, 10 days after BDNF i.t. or two weeks after CCI-SN (Fig. 7).  This might suggest that 
not only TrkB but also the low affinity BDNF receptor p75 could be implicated in the 
maintenance of BDNF-i.t.- as well as CCI-SN-induced hyperalgesia, as proposed by Obata et 
al. (2006). Further investigations will have to assess this point as well as exploring whether 
cyclotraxin B would affect not only the maintenance but also the development of CCI-SN-
induced neuropathic pain. 
Such close similarities in TrkB-dependent hyperalgesia-like behavior in BDNF i.t.- and CCI-SN-
rats led us to investigate respective underlying physiopathological mechanisms. In the case 
of CCI-SN, neural injury resulted in upregulation of transcripts encoding ATF3, microglial 
activation markers OX-42 and Iba1 as well as downstream products including the 
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proinflammatory cytokine IL-6, BDNF and the NR2B subunit of NMDA receptors in both 
spinal and DRG tissues, in line with previous reports (Latrémolière et al., 2008; Zhuo et al., 
2011). That microglial activation and downstream signaling cascades play a key role in the 
induction of neuropathic pain after nerve lesion is notably supported by data showing that 
the administration of minocycline, a microglial inhibitor, attenuates neuropathic pain 
development in nerve lesioned rats (Latrémolière et al., 2008). In contrast, no sign of neural 
injury, as shown by unchanged expression of ATF3, and no evidence of microglia activation, 
neither in DRG nor in spinal cord tissues after i.t. BDNF indicating that the latter treatment 
did not really mimic the complex neuropathic condition induced by CCI-SN. Accordingly, 
immunolabeling of the microglial activation marker, P-p38, was enhanced in CCI-SN rats but 
not in BDNF i.t. rats (Fig. 9). In contrast, Zhou et al. (2010) previously reported that a 
transient microglial activation could be induced by i.t. administration of BDNF, suggesting 
that our investigations only in unstimulated BDNF i.t. rats were not enough to reach a clear-
cut conclusion. This led us to submit BDNF i.t. rats to a sustained unilateral mechanical, non 
nociceptive, stimulation of the hindlimb, which was previously shown to allow the detection 
of nociceptive pathway sensitization (Kayser et al., 2010). A clear-cut increase in the density 
of P-p38 immunoreactive cells was thus observed within the dorsal horn of the lumbar cord 
in BDNF i.t. rats, indicating that microglial activation might also occur in these animals.  
Of all the transcripts investigated in our studies, only the one encoding BDNF (exon IX) was 
found to be upregulated within the dorsal horn of BDNF i.t. rats, in line with previous data 
showing that this neurotrophic factor can promote its own synthesis (Cheng et al., 2011; 
Zheng et al., 2012).  Such autocrine action of BDNF very probably explains why a single i.t. 
administration of this neurotrophin produced a long-lasting TrkB-mediated neuropathic 
pain-like effect. Whether similar BDNF autocrine effect also underlay the maintenance of 
CCI-SN-induced neuropathic pain will have to be assessed by comparing the effects of 
cyclotraxin B on the expression of genes downstream of TrkB activation in both CCI-SN and 
BDNF-it rats.  
In further support to the existence of close homology between the effects of BDNF i.t. and 
CCI-SN, drugs used to treat neuropathic pain in humans such as pregabalin, tapentadol and 
morphine (Finnerup et al., 2015) were found to be equally effective to reduce hyperalgesia 
in both models. In contrast, amitriptyline, duloxetine and clonazepam were equally 
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ineffective under the acute treatment conditions used in our studies, in line with convergent 
data showing that these drugs, especially antidepressants, have to be administered 
chronically to exert significant anti-hyperalgesic effects (Benbouzid et al., 2008). However, 
this was not the case with agomelatine since acute administration of this antidepressant 
significantly reduced hyperalgesia in both models. Agomelatine is an agonist at melatonergic 
MT1 and MT2 receptors and an antagonist at 5-HT2B and 5-HT2C receptors (de Bodinat et al., 
2010), which are all relevant targets for neuropathic pain alleviation (Ambriz-Tututi et al., 
2009; Viguier et al., 2013). Accordingly, concomitant actions at these receptors might 
account for its unique antihyperalgesic efficacy when compared to other antidepressants 
under acute treatment conditions. Interestingly, agomelatine was found to enhance BDNF 
expression in the rat hippocampus (Soumier et al., 2009), and it would therefore be of 
interest to assess its effect on BDNF expression  and TrkB activity at the spinal level.  
Interestingly, the NMDA receptor antagonist ketamine was also found to inhibit both CCI-SN- 
and BDNF i.t.-induced hyperalgesia, as expected from convergent data showing that BDNF-
induced synaptic sensitization is mediated through facilitation of NMDA receptor-dependent 
glutamatergic nociceptive pathways (Geng et al., 2010; Chen et al., 2014). As mRNA 
encoding the NR2B subunit of NMDA receptors was not upregulated 10 days after BDNF i.t. 
injection, when hyperalgesia had fully developed, it can be inferred that BDNF did not induce 
NR2B transcription but most probably promoted its activation via phosphorylation, as 
previously reported in cortical and hippocampal neurons (Lin et al., 1998).  
In addition to promoting NMDA receptor-mediated neurotransmission, BDNF is known to 
downregulate the expression and activity of the KCC2 K+/Cl- co-transporter, which reduces 
the hyperpolarizing/inhibitory properties of GABA (Coull et al., 2005). Whether this 
mechanism also contributes to BDNF i.t.- induced hyperalgesia/allodynia is an interesting 
possibility to be addressed in future investigations.  
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Legends to figures 
  
Fig. 1 Time-course development of mechanical hyperalgesia and allodynia in CCI-SN- versus 
BDNF i.t.- rats. Pressure threshold values to trigger vocalization in the Randall-Selitto test 
(mechanical hyperalgesia, A, B) or hindpaw withdrawal in the von Frey filaments test 
(mechanical allodynia, C, D) were determined at various times (abscissa) after sciatic nerve 
ligation (A, C) or i.t. injection of BDNF (B, D). Parallel measurements were made in sham-
operated rats (A, C) and in i.t. saline-injected rats  (B, D). Each point is the mean ± S.E.M. of 
6-7 animals per group. * P<0.05, ** P < 0.01, *** P < 0.001 compared to respective controls, 
two way ANOVA with repeated measures, Bonferroni test. 
  
Fig. 2 Respective characteristics of maximal hyperalgesia induced by CCI-SN versus BDNF i.t. 
in rats. Pressure threshold values to trigger hindpaw withdrawal (PWT) and vocalization (VT) 
in the Randall-Selitto test were determined 15 days after sciatic nerve ligation (A) or 10 days 
after i.t. injection of BDNF (B). Parallel measurements were made at the same times in sham-
operated rats (A) and saline i.t. injected rats (B). Each point is the mean + S.E.M. of 15-18 
animals per group. * P<0.05, ** P < 0.01, *** P < 0.001 compared to respective controls, 
Student’s t test. 
  
Fig. 3 Anti-hyperalgesic effects of pregabalin (A, B) and ketamine (C, D) in BDNF i.t. (A, C) and 
CCI-SN (B, D) rats. Acute administration of pregabalin (30 mg/kg i.p.), ketamine (50 mg/kg 
i.p.), or saline was performed (arrow, 0 on abscissa) 15 days post-surgery in CCI-SN rats or 10 
days after i.t. injection of BDNF (3.0 ng). Pressure threshold values to trigger vocalization in 
the Randall-Selitto test were determined at various times after treatment (D1 : 24 h post-
treatment). Each point is the mean ± S.E.M. of 6-8 animals per group. C on abscissa : Control 
(naïve) rats (prior to CCI-SN surgery or i.t. BDNF). * P < 0.05, ** P < 0.01 compared to 
respective values in saline-treated rats, two way ANOVA with repeated measures, 
Bonferroni test. 
 
Fig. 4 Anti-hyperalgesic effects of morphine (A, B) and tapentadol  (C, D) in BDNF i.t. (A, C) 
and CCI-SN (B, D) rats. The same protocols as those described in the legend to figure 3 were 
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used but with morphine (3 mg/kg s.c.) or tapentadol (10 mg/kg i.p.). Each point is the mean 
± S.E.M. of vocalization threshold values in 6-10 animals per group. * P < 0.05 compared to 
respective values in saline-treated rats, two way ANOVA with repeated measures, 
Bonferroni test. 
 
Fig. 5 Effects of agomelatine (A, B) and amitriptyline (C, D) on hyperalgesia induced by i.t. 
BDNF (A, C) or CCI-SN (B, D) in rats. Agomelatine (45 mg/kg i.p.), amitriptyline (10 mg/kg 
i.p.), or their respective vehicle was injected (arrow, 0 on abscissa) under the same 
conditions as those described for other drugs in Figs 3-4. Each point is the mean ± S.E.M. of 
vocalization threshold values in 6-8 animals per group. * P < 0.05 compared to respective 
values in vehicle (A,B: 1% HEC; C,D: saline)-treated rats, two way ANOVA with repeated 
measures, Bonferroni test. 
  
Fig. 6 Prevention by cyclotraxin B of i.t. BDNF-induced hyperalgesia. Cyclotraxin B (20 mg/kg 
i.p.) or saline was injected twice (arrows, 0 on abscissa), 15 minutes before and 15 minutes 
after i.t. administration of BDNF (3.0 ng). Pressure threshold values to trigger hindpaw 
withdrawal (A) and vocalization (B) in the Randall-Selitto test were determined at various 
times (abscissa), up to day 8 post BDNF i.t. Each point is the mean ± S.E.M. of 5-7 animals per 
group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to pressure threshold values just prior 
to i.t. administration of BDNF (0 on abscissa; range values as grey band), one way ANOVA 
with repeated measures, PLSD test. § P < 0.05, §§ P < 0.01, §§§ P < 0.001 compared to 
respective values in rats treated with saline + BDNF i.t., two way ANOVA with repeated 
measures, Bonferroni  test. 
 
Fig. 7 Reversal by cyclotraxin B of mechanical hyperalgesia induced by CCI-SN (A, C) or i.t. 
BDNF (B, D). Cyclotraxin B (20 mg/kg i.p.) or saline was injected twice (0 on abscissa), with a 
30 min interval, on day 15 after CCI-SN (A,C) or on day 10 after i.t. administration of BDNF 
(B,D). Pressure threshold values to trigger vocalization in the Randall-Selitto test were then 
determined at various times (abscissa), up to day 20 (A) or day 12 (B) after these acute 
injections. Each point is the mean + S.E.M. of 6 animals per group. C on abscissa : Control 
(naive) rats (prior to CCI-SN surgery or i.t. BDNF). * P < 0.05 compared to respective values in 
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saline-treated groups, two way ANOVA with repeated measures, Bonferroni test. C,D : Bars 
are the mean + S.E.M. of AUCs (g x min) derived from the time-course changes in pressure 
threshold values in CCI-SN (C from A) or BDNF i.t. (D from B) rats. *** P < 0.001 compared to 
respective saline-treated groups, Student’s t test. 
  
Fig. 8 Tissue levels of transcripts encoding ATF3, OX-42, Iba1, GFAP, IL-6, BDNF and NR2B in 
the spinal cord and dorsal root ganglia of CCI-SN- and BDNF i.t.- rats. RT-qPCR 
determinations were made in dorsal lumbar enlargement and L4-L6 DRG 15 days after CCI-
SN (dorsal quadrant of lumbar enlargement  and DRG ipsilateral to CCI) and 10 days after 
BDNF i.t. Parallel measurements were made in respective controls (sham-operated rats and 
saline i.t. rats). Data are expressed as the ratio of specific mRNA over GaPDH mRNA 
[R.Q.(A.U.)]. Each bar is the mean + S.E.M. of 7-12 animals per group.  * P < 0.05, ** P < 0.01, 
*** P < 0.001 compared to respective levels in sham-operated (CCI-SN) or saline-treated 
(BDNF i.t.) rats, Student’s t test. 
   
 Fig. 9 Immunohistochemical labeling of the microglial marker P-p38 in the lumbar 
enlargement of the spinal cord in CCI-SN- and BDNF i.t.- rats.  A – Left: Typical 
photomicrographs showing P-p38 immunoreactive cells (black dots) in coronal sections from 
a sham-operated rat and a CCI-SN rat, 15 days after surgery on the right side; Right: Bar 
graphs of the mean number (+ S.E.M.) of P-p38 immunoreactive cells counted within the 
right (ipsilateral to surgery) superficial (I-II) and deep (III-IV-V) laminae - delimited by dotted 
lines on micrographs - of 26-34 sections from 4 rats in each group. *** P<0.001, Student’s t 
test. Scale bar: 250 m.  B – Left: Typical micrographs showing P-p38 immunoreactive cells 
(black dots) in coronal sections from a BDNF i.t.- and a saline i.t.- rat 24 hours after non-
noxious mechanical stimulation of right hindpaw (see Experimental procedures); Right: Bar 
graphs of the mean number (+ S.E.M.) of P-p38 immunoreactive cells counted within the 
superficial (I-II) and deep (III-IV-V) laminae on the right side of 26-30 sections from 3-4 rats in 
each group. ** P<0.01, *** P<0.001, one way ANOVA, Newman-Keuls test. Scale bar: 250 
m 
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